Pyridine-2-thiol 1-oxide, sodium salt

Acute Toxicity: dermal

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1987

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

EPA OPP 81-2 (Acute Dermal Toxicity)

GLP compliance:

yes

Test material

Test material information

Constituent 1

Reference substance name:

Pyridine-2-thiol 1-oxide, sodium salt

EC Number:

223-296-5

EC Name:

Pyridine-2-thiol 1-oxide, sodium salt

Cas Number:

3811-73-2

Molecular formula:

C5H5NOS.Na

IUPAC Name:

sodium (1-oxo-1λ⁵-pyridin-2-yl)sulfanide

Details on test material:

- Analytical purity: 43.78%
- Lot/batch No.: F113D1

Test animals

Species:

rabbit

Strain:

New Zealand White

Sex:

male/female

Details on test animals or test system and environmental conditions:

-Source: Ace Animals
-Age: 8 weeks
-Weight: Male 2.1-3.0 kg, females 2.1-2.8 kg

Administration / exposure

Type of coverage:

occlusive

Vehicle:

unchanged (no vehicle)

Details on dermal exposure:

-Coverage: 10% of body surface

Duration of exposure:

-Exposure duration: 24h
-Post exposure period: 14 days
-Removal of test substance: Washed iff gently with water and wiped with clean gauze

Doses:

1500, 1650, 1800, & 2000 mg/kg

No. of animals per sex per dose:

5

Results and discussion

Effect levels

Effect levels 1

Sex:

male

Dose descriptor:

LD50

Effect level:

1 900 mg/kg bw

Effect levels 2

Sex:

female

Dose descriptor:

LD50

Effect level:

1 800 mg/kg bw

Effect levels 3

Sex:

male/female

Dose descriptor:

LD50

Effect level:

1 800 mg/kg bw

Mortality:

Mortality: 1 male and 2 females died 1 day after dosing at 1500 mg/kg
1 female died at 1 day after dosing,
1 female died at day 2 after dosing,
1 male died at day 4 after dosing
1 male died on day 16 after dosing of 1650 mg/kg (2 additional days were added to the observation period due to body weight loss)
2 males and 2 females died 1 day after dosing after 1800 mg/kg.
2 males and 3 females on day 1 after dosing,
1 female on day 2 after dosing,
1 male on day 14 after dosing at 2000 mg/kg

Clinical signs:

other: Systemic: few feces, diarrhea, lethargy, yellow nasal discharge, emaciation, prostration, negative righting reflex, ataxia, ptosis, bloated abdomen, unkempt appearance, decreased body temperature, soilingof the anogenital are, pupilary dilation, wetness o

Gross pathology:

On necropsy animals dying before completion of the observation period showed abnormalities of the lungs, liver, gall bladder, spleen, gastrointestinal tract, kidneys, urinary bladder, brown and red staining of the nose/mouth area, red coloration of the body wall and fat, excessive fluid in the peritoneal cavity and at the site of the treated skin.
Necropsy of the surviving animals revealed abnormalities of the lungs, kidneys, gastrointestinal tract, yellow staining of the nose/mouth area, and of the skin at the site of application.

Applicant's summary and conclusion

Conclusions:

LD50 = 1800 mg/kg bw. The information contained within this robust summary document comes from studies which are in the ownership of Arch Chemicals Inc. and which are protected in several regions globally. This information may not be used for any purpose other than in support of the Chemical safety Report submitted by Arch Chemicals Inc. under Regulation EC 1907/2006.